Carolina Biooncology Institute

Huntersville, North Carolina 28078

15 studies enrolling now · 72 studies all time

What they study most

Advanced Breast Cancer, Advanced Breast Carcinoma, Advanced Cancer, Advanced Malignancies, Advanced Solid Tumor, Advanced Solid Tumor, Adult, Advanced Solid Tumors, Advanced Solid Tumors Cancer, Advanced Solid Tumors or Lymphomas, Advanced Unresectable Solid Tumor, Advanced or Metastatic Solid Tumors, Advanced/Metastatic Solid Tumors

Studies at this site

• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer — Recruiting now
• Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors — Recruiting now
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors — Recruiting now
• Study of XB010 in Subjects With Solid Tumors — Recruiting now
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations — Recruiting now
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) — Recruiting now
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors — Recruiting now
• A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of HS-20110 in Participants With Advanced Solid Tumors — Recruiting now
• Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors — Recruiting now
• A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. — Recruiting now
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors — Recruiting now
• Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors — Recruiting now
• Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors — Recruiting now
• A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors — Recruiting now
• A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors — Recruiting now
• Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors — Recruiting now
• Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors — Completed
• XTX202 in Patients With Advanced Solid Tumors — Completed
• A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors — Stopped early
• Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors — Stopped early
• A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers — Completed
• Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors — Running, not enrolling
• A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — Running, not enrolling
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors — Stopped early
• First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors — Completed
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors — Completed
• MGC018 With or Without MGA012 in Advanced Solid Tumors — Stopped early
• Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients — Stopped early
• A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors — Stopped early
• A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer — Stopped early
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies — Completed
• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab — Completed
• Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies — Completed
• Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer — Completed
• A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. — Running, not enrolling
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies — Completed
• A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies — Completed
• A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies — Completed
• A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors — Stopped early
• A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors — Status unconfirmed
• ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — Completed
• Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies — Status unconfirmed
• FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors — Stopped early
• Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors — Stopped early
• TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers — Completed